Cover Image

Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation

Outcomes and prognostic factors of reduced intensity-conditioned allo-SCT (RIC allo-SCT) for multiple myeloma (MM) relapsing or progressing after prior autologous (auto)-SCT are not well defined. We performed an analysis of 413 MM patients who received a related or unrelated RIC allo-SCT for the tre...

Full description

Saved in:
Bibliographic Details
Main Authors: Auner, Holger (Author) , Szydlo, R. (Author) , van Biezen, A. (Author) , Iacobelli, S. (Author) , Gahrton, G. (Author) , Milpied, N. (Author) , Volin, L. (Author) , Janssen, J. (Author) , Nguyen Quoc, S. (Author) , Michallet, M. (Author) , Schoemans, H. (Author) , el Cheikh, J. (Author) , Petersen, E. (Author) , Guilhot, F. (Author) , Schönland, Stefan (Author) , Ahlberg, L. (Author) , Morris, C. (Author) , Garderet, L. (Author) , de Witte, T. (Author) , Kröger, N. (Author)
Format: Article (Journal)
Language:English
Published: 27 May 2013
In: Bone marrow transplantation
Year: 2013, Volume: 48, Issue: 11, Pages: 1395-1400
ISSN:1476-5365
DOI:10.1038/bmt.2013.73
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/bmt.2013.73
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/bmt201373
Get full text
Author Notes:HW Auner, R Szydlo, A van Biezen, S Iacobelli, G Gahrton, N Milpied, L Volin, J Janssen, S Nguyen Quoc, M Michallet, H Schoemans, J el Cheikh, E Petersen, F Guilhot, S Schönland, L Ahlberg, C Morris, L Garderet, T de Witte and N Kröger, on behalf of the plasma cell dyscrasia sub-committee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Description
Summary:Outcomes and prognostic factors of reduced intensity-conditioned allo-SCT (RIC allo-SCT) for multiple myeloma (MM) relapsing or progressing after prior autologous (auto)-SCT are not well defined. We performed an analysis of 413 MM patients who received a related or unrelated RIC allo-SCT for the treatment of relapse/progression after prior auto-SCT. Median age at RIC allo-SCT was 54.1 years, and 44.6% of patients had undergone two or more prior auto-SCTs. Median OS and PFS from the time of RIC allo-SCT for the entire population were 24.7 and 9.6 months, respectively. Cumulative non-relapse mortality (NRM) at 1 year was 21.5%. In multivariate analysis, CMV seronegativity of both patient and donor was associated with significantly better PFS, OS and NRM. Patient-donor gender mismatch was associated with better PFS, fewer than two prior auto-SCT was associated with better OS, and shorter time from the first auto-SCT to the RIC allo-SCT was associated with lower NRM. The results of this study identify patient and donor CMV seronegativity as the key prognostic factor for outcome after RIC allo-SCT for MM relapsing or progressing after prior auto-SCT.
Item Description:Gesehen am 23.10.2020
Physical Description:Online Resource
ISSN:1476-5365
DOI:10.1038/bmt.2013.73

Similar Items